Pharma channel feed

Bio­gen ends agree­ment with Acor­da for mul­ti­ple scle­ro­sis drug Fampyra

Last year

Want to make bet­ter phar­ma ads? Try us­ing hu­mor and more brand­ing, Kan­tar an­a­lyst says

Last year
Marketing

FDA de­ter­mines GLP-1s not linked to sui­ci­dal thoughts or ac­tions in pre­lim­i­nary re­view

Last year
FDA+

FDA de­vel­ops pi­lot to har­mo­nize in­ter­na­tion­al gene ther­a­py reg­u­la­tions

Last year
Cell/Gene Tx
FDA+

FDA ap­proves im­port of French an­tibi­otics to com­bat syphilis drug short­age 

Last year
Manufacturing

Madri­gal says it's 'well on the way' to po­ten­tial NASH launch ahead of FDA de­ci­sion: #JPM24

Last year

Sanofi says it may look at next gen­er­a­tion of weight loss drugs: #JPM24

Last year
R&D

How gener­ic drug spon­sors can ask FDA to re­con­sid­er ap­pli­ca­tions: new draft guid­ance ex­plains

Last year
FDA+

Af­ter 'grow­ing up' last year, Mod­er­na warns of loss­es and charts path back to prof­its: #JPM24

Last year
R&D

Paul Hud­son is 'open-mind­ed' to M&A as he plots Sanofi's trans­for­ma­tion: #JPM24

Last year

#JPM24 quick hits: Vibe check; Maze’s next turn; AI at phar­ma com­pa­nies + more

Last year
Deals
AI

Health­care gi­ant Gri­fols ac­cused of ma­nip­u­lat­ing fi­nances by short sell­er Gotham City, stock plum­mets 

Last year
Financing

Lu­pus drug mar­ket grow­ing as physi­cians adopt new­er op­tions — and look for more, re­search finds

Last year
Marketing

FDA chief taps Eliz­a­beth Jung­man as new chief of staff, start­ing lat­er this month

Last year
FDA+

As Con­gress de­bates or­phan re­forms, new analy­sis finds 65% of or­phan drugs ap­proved for a sin­gle rare dis­ease

Last year
FDA+

MiMedx re­ceives FDA warn­ing let­ter over Ax­iofill man­u­fac­tur­ing con­cerns

Last year
FDA+
Manufacturing

RTW, Bay­er back Cy­to­ki­net­ics-al­lied Ji Xing Phar­ma­ceu­ti­cals with $162M: #JPM24

Last year
Financing
China

GSK to buy asth­ma biotech Aio­los Bio for up to $1.4B three months af­ter start­up emerged: #JPM24

Last year
Deals
China

#JPM24 quick hits: A 'great year for M&A'; an op­ti­mistic Sarep­ta; Pfiz­er's CEO + more

Last year
Deals
R&D

Pfiz­er CEO says it's back to ba­sics af­ter painful 2023 for in­vestors: #JPM24

Last year
R&D

Physi­cians are on board with mR­NA vac­cines, but wor­ry about pa­tient mis­in­for­ma­tion, sur­vey finds

Last year
Marketing

Sen­ate health com­mit­tee in­ves­ti­gates in­haler man­u­fac­tur­ers for high prices

Last year
FDA+

Ver­tex backs out of agree­ment with CRISPR Ther­a­peu­tics for stem cell ther­a­py can­di­date in di­a­betes

Last year
Deals

J&J makes $2B push in­to AD­Cs with Am­brx buy­out in on­col­o­gy deal spree: #JPM24

Last year
Deals
First page Previous page 80818283848586 Next page Last page
A service from the Financial Times